TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control; Phase 3. Sponsor: Merck & Co. Inc. (U.S. sites coordinated by the Duke Clinical Research Institute (DCRI), International sites by the Oxford Clinical Trials Group).
EXenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A randomized, placebo-controlled clinical trial to evaluate cardiovascular outcomes after treatment with Exenatide once weekly in patients with Type 2 diabetes mellitus. Phase 3b/4. Sponsors: Amylin Pharmaceuticals, Inc. and Eli Lilly and Co.
For more information about these studies, please contact Teri Lavenbarg, APRN, FNP-BC, PNP,-BC, CDE.